Dear Colleagues,

Rapid growth in industrial research and development of antibody drug conjugate (ADC) production has occurred over the last two decades, resulting in more than 10 ADCs that have received market approval by the Food and Drug Administration as monotherapies. During this timeframe, significant efforts aimed at generating “best in class” ADCs have been undertaken including ADC target selection, payload diversity, cleavable linker design, hydrophilic linker design, site-specific conjugation technology, and application of next generation clinical and translational strategies. Furthermore, novel applications such as multi-specific antibody-based bioconjugates, antibody immobilization, antibody sensors, antibody-oligonucleotide conjugates, or antibody-protac conjugates have emerged. In this special issue, we will highlight recent work, selected from across the ADC field, that describes novel and important laboratory and clinical advances.

Dr. Brian A. Mendelsohn

Guest Editor